Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial.

Summary: Imagine you have a tough cancer called sarcoma that has spread, and standard treatments aren't working anymore. Doctors recently tested a new combination of two drugs: sintilimab and anlotinib. They gave this mix to 42 patients in a clinical trial, and the results were very hopeful! About 31% of patients saw their tumors shrink, and the cancer stopped growing in over 75% of them for a while. The side effects were mostly mild and manageable. Even better, doctors found a special clue in the immune system (called "TLS") that can predict exactly who will respond best to this treatment. This means new hope and smarter, more personalized care for patients who need it most!